Evidence map›Paper›PMID 37961431›Full record

ArticleResearch square2023

Rationally-defined microbial consortia suppress multidrug-resistant proinflammatory Enterobacteriaceae via ecological control.

Kenya Honda, Munehiro Furuichi, Takaaki Kawaguchi, Marie-Madlen Pust, Keiko Yasuma-Mitobe, Damian Plichta, Naomi Hasegawa, Takashi Ohya, Shakti Bhattarai, Satoshi Sasajima and 21 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. A comparativeFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 7 institutions in 2 countries.

Kenya HondaKeio University School of Medicine.ORCID https://orcid.org/0000-0001-8937-9835
Munehiro FuruichiKeio University School of Medicine.ORCID https://orcid.org/0000-0001-7742-1135
Takaaki KawaguchiKeio University School of Medicine.
Marie-Madlen PustBroad Institute of MIT and Harvard.
Keiko Yasuma-MitobeKeio University School of Medicine.
Damian PlichtaBroad Institute.ORCID https://orcid.org/0000-0002-6555-2557
Naomi HasegawaKeio University School of Medicine.
Takashi OhyaKeio University School of Medicine.
Shakti BhattaraiUMass Chan Medical School.
Satoshi SasajimaKeio University School of Medicine.
Aoto YoshimasaJSR-Keio University Medical and Chemical Innovation Center.
Timur TuganbaevKeio University School of Medicine.
Mizuki YaginumaKeio University School of Medicine.
Masahiro UedaORCID https://orcid.org/0000-0001-8814-7071
Nobuyuki OkahashiOsaka Universtiy.ORCID https://orcid.org/0000-0001-9582-355X
Kimiko AmafujiKeio University School of Medicine.
Yuuko KiridooshiJSR Corp.
Kayoko SugitaKeio University School of Medicine.
Martin StražarBroad Institute of MIT and Harvard.
Ashwin SkellyKeio University School of Medicine.ORCID https://orcid.org/0000-0002-1565-3376
Wataru SudaRIKEN Center for Integrative Medical Sciences.
Masahira HattoriRIKEN IMS.
Nobuhiro NakamotoKeio University School of Medicine.ORCID https://orcid.org/0000-0001-5203-7444
Silvia CaballeroImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center.
Jason NormanVedanta Biosciences Inc.ORCID https://orcid.org/0000-0001-5049-8415
Bernat OlleVedanta Biosciences.
Takeshi TanoueKeio University School of Medicine.ORCID https://orcid.org/0000-0003-3639-8834
Makoto AritaRIKEN Center for Integrative Medical Sciences.ORCID https://orcid.org/0000-0001-9902-0463
Vanni BucciUMass Chan Medical School.
Koji AtarashiKeio University School of Medicine.ORCID https://orcid.org/0000-0001-5422-0736
Ramnik XavierMassachusetts General Hospital.ORCID https://orcid.org/0000-0002-5630-5167
Keio University · JPBroad Institute · USRIKEN Center for Integrative Medical Sciences · JPUniversity of Massachusetts Chan Medical School · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USVedantra Pharmaceuticals (United States) · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Determinants of inception of inflammation in inflammatory bowel diseasesR01DK127171 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANANTHAKRISHNAN, ASHWIN N, XAVIER, RAMNIK J · 2021 to 2025
$5.4M
Identification and Characterization of Microbial Metabolites in ImmunityR01AI172147 · NIAID · BROAD INSTITUTE, INC. · PI Daniel Bartholomew Graham, Ramnik J Xavier · 2022 to 2026
$3.9M
Cardiovascular disease, metabolic syndrome, microbes and metabolites in FHSR01HL157717 · NHLBI · BROAD INSTITUTE, INC. · PI XAVIER, RAMNIK J · 2022 to 2025
$3.9M
NHLBI NIH HHS R01 HL157717NIAID NIH HHS R01 AI172147NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK127171
6 · The paper itself

Abstract

Persistent colonization and outgrowth of pathogenic organisms in the intestine may occur due to long-term antibiotic usage or inflammatory conditions, which perpetuate dysregulated immunity and tissue damage

Identifiers

PMID37961431
PMCPMC10635318
OpenAlexW4387873925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.